Incyte's average Accounts Receivable for the
three
months ended in Jun. 2022 was $623 Mil. Incyte's Revenue for the
three
months ended in Jun. 2022 was $911 Mil.
Hence, Incyte's Days Sales Outstanding for the
three
months ended in Jun. 2022 was 62.34.
The historical rank and industry rank for Incyte's Days Sales Outstanding or its related term are showing as below:
INCY'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.29 Med: 50.71 Max: 67.12
Current: 61.92
During the past 13 years, Incyte's highest Days Sales Outstanding was 67.12. The lowest was 33.29. And the median was 50.71.
INCY's Days Sales Outstanding is ranked better than 57.31% of 876
companies
in the Biotechnology industry
Industry Median: 71.08
vs INCY: 61.92
Incyte's Days Sales Outstanding
increased
from Jun. 2021 (54.02) to Jun. 2022 (62.34).
Incyte Days Sales Outstanding Historical Data
The historical data trend for Incyte's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Incyte Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Days Sales Outstanding
49.31
55.66
52.11
54.12
67.12
Incyte Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Days Sales Outstanding
54.02
53.59
59.91
73.34
62.34
Competitive Comparison
For the Biotechnology subindustry, Incyte's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte Days Sales Outstanding Distribution
For the Biotechnology industry and Healthcare sector, Incyte's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Incyte's Days Sales Outstanding falls into.
Incyte Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (NAS:INCY) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Incyte Days Sales Outstanding Related Terms
Thank you for viewing the detailed overview of Incyte's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.03(0.05%) Volume: 1,615,568 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:INCY has been successfully added to your 
